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Objective: Multiple endocrine neoplasia type 2 (MEN 2) is a genetic disease characterized by medullary
thyroid carcinoma (MTC) associated (MEN 2A and 2B) or not familial MTC (FMTC) with other
endocrine neoplasia due to germline RET gene mutations. The prevalence of these rare genetic diseases
and their corresponding RET mutations are unknown due to the small size of the study population.
Methods: We collected data on germline RET mutations of 250 families with hereditary MTC followed
in 20 different Italian centres.
Results and conclusions: The most frequent RET amino acid substitution was Val804Met (19.6%)
followed by Cys634Arg (13.6%). A total of 40 different germline RET mutations were present. Six
families (2.4%) were negative for germline RET mutations. The comparison of the prevalence of RET
germline mutations in the present study with those published by other European studies showed a
higher prevalence of Val804Met and Ser891Ala mutations and a lower prevalence of Leu790Phe
and Tyr791Phe (P!0.0001). A statistically significant higher prevalence of mutations affecting
non-cysteine codons was also found (P!0.0001).
Furthermore, the phenotype data collection showed an unexpected higher prevalence of FMTC
(57.6%) with respect to other MEN 2 syndromes (34% MEN 2A and 6.8% of MEN 2B). In conclusion,
we observed a statistically significant different pattern of RET mutations in Italian MEN 2 families with
respect to other European studies and a higher prevalence of FMTC phenotype. The different ethnic
origins of the patients and the particular attention given to analysing apparently sporadic MTC for RET
germline mutations may explain these findings.
European Journal of Endocrinology 163 301–308Introduction
The human RET gene maps on 10q11.2, and is
composed of 21 exons with a size of about 55 kb (1).
The RET gene encodes a tyrosine kinase transmembranendocrinologyreceptor (2) characterized by three different domains: the
extracellular domain, the transmembrane domain, and
the intracellular tyrosine kinase domain. TheRETgene is
expressed in a variety of neuronal cell lineages including
thyroid C cells and adrenal medulla (3).DOI: 10.1530/EJE-10-0333
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Different types of germline RET mutation in Italian kindred
Val804Met Cys634Arg Cys634Tyr Ser891Ala
Met918Thr Glu768Asp Leu790Phe Cys634Phe
Cys618Ser No mut Cys634Gly Cys634Ser
Cys618Arg Cys620Arg Cys634Trp Cys620Ser
Val804Leu Cys630Tyr Cys609Tyr Cys618Gly
Cys618Tyr Met918Val Tyr791Phe Val648Iso
Ala883Thr Arg694Gln Cys515Ser Cys609Arg
Cys609Gly Cys609Phe Cys609Ser Cys611Gly
Cys620Gly Cys620Phe Cys630Arg Cys634Val
Lys666Met Met848Thr Ser904Phe Thr338Ile
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Figure 1 Prevalence of 40 different germline RET mutations in an
Italian study of 250 MEN 2 families: Val804Met is the most prevalent
RET mutation in this study.
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Figure 2 Prevalence of altered RET codons in an Italian study of
250 MEN 2 families: codon 634 is the most frequently altered codon
in this study.
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germline point mutations of the RET proto-oncogene
are causative events in multiple endocrine neoplasia
type 2 (MEN 2) (4–6). MEN 2 are autosomal dominant
inherited syndromes characterized by the presence of
medullary thyroid carcinoma (MTC) in 100% of cases,
associated or not familial MTC (FMTC) with other
endocrine tumors like pheochromocytoma (PHEO)
and/or parathyroid adenomas (hyperPTH) in MEN 2A
or only PHEO in MEN 2B (7). Other non-endocrine
diseases are typically present in MEN 2B (mucosal
neurinomas, megacolon, corneal nerve hypertrofia,
and habitus marphanoid) (8, 9) and occasionally in
MEN 2A (cutaneous lichen amyloidosis) (10, 11).
Finally, Hirschsprung’s disease can be associated with
both MEN 2A and MEN 2B (12, 13).
The incidence of the MEN 2 syndromes is unknown.
Because MTC represents only 5–10% of all thyroid
tumors, being sporadic in 75% of cases and familial in
25% of cases, the prevalence of MEN 2 isw1–3% of all
thyroid malignant tumors. Since thyroid tumors rep-
resent only 1% of all human cancers (14), it is evident
that MEN 2 is a very rare disease, and only cooperative
studies have been able to include an appropriate number
of affected subjects and families to accurately correlate
RET mutation and MEN 2 syndrome (15).
The number and type of RET point mutations
associated with MEN 2 have been growing over the last
10 years, especially after the introduction of RET
genetic screening in the work-up of all patients with
MTC (16, 17). Several studies demonstrated the presence
of a RET germline mutation in 5–10% of apparently
sporadic cases, mainly located in non-cysteine codons
(18–20). Owing to the rarity of the MEN 2 syndromes,
the prevalence of the different RET mutations is not well
defined, and it is not clear whether specificmutations are
more prevalent in distinct geographic areas (21–23).
So far, there are only four published European studieswww.eje-online.orgcollecting data from several centres in which the
prevalence and distribution of different RET mutations
have been investigated (2, 23–25).
The aims of the present study were i) to collect RET
genetic screening data from as many Italian families as
possible affected by MEN 2/FMTC, ii) to analyze the
distribution and frequency of RET mutations in this
study of families, and iii) to compare the type and
prevalence of RET mutations to those reported in
previous studies of European families of affected
individuals.Patients and methods
The majority of the Italian centres involved in the
diagnosis and treatment of thyroid carcinoma were
invited to complete a form containing the following
information for any patient with hereditary or sporadic
MTC analyzed by RET genetic screening: i) name and
surname of the index case, ii) other surnames in the
same family to avoid multiple inclusion of the same
family members, iii) type of RET mutation, and iv) MEN
2 phenotype according to the definitions reported in the
recent American Thyroid Association guidelines on
MTC management (26).
A database recording the collected information was
organized at Pisa University Hospital, which is a
national referral centre for the diagnosis and treatment
of thyroid cancer and where 103 MTC families are
currently followed. Only Italian patients were included
in the study. The study was approved by the Internal
Reviewing Board of the Department of Endocrinology
and Metabolism in Pisa.
All patients signed an informed consent to genetic
analysis.
We also ascertained that in each centre, the RET
mutation analysis had been performed according to
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Figure 3 Pedigrees of families classified as ‘Others’. Cases with reported age have been tested for the RET mutation and RET-positive
cases are marked with an asterisk. Family A: only the 8-year-old child was affected with Hirschsprung’s disease; neither MTC nor elevated
serum calcitonin (CT) was found in the index case and family members; Family B: RET-positive cases found by screening of normal
persons; neither MTC nor elevated serum CT was found in this family; Families C and D: elevated serum CT and C cell hyperplasia in cases
with RET mutation but not in the other members of the families.
Prevalence of MEN 2 syndromes in Italy 303EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010) 163the same procedure. Briefly, RET gene mutation
screening was performed on genomic DNA extracted
from the blood of patients with hereditary or sporadic
MTC, and analyzed by sequence analysis as previously
reported (18).
As inclusion criterion, the centres were asked to
confirm that they routinely investigated for germline
mutations, all cases of MTC, also those apparently
sporadic, and that at least the sixmore frequently affected
exons (i.e 10–11, 13–16) were commonly studied.Statistical analysis
Data analysis was performed using StatView 4.5
software (Abacus Concepts Inc., Berkley, CA, USA).
We adopted the c2 test to analyse data collected from
participating centres. A P value!0.05 was regarded to
be statistically significant.Results
We collected clinical and molecular data on hereditary
MTC patients from 20 different Italian centres with a
total of 250 families. In a few cases, different members of
the same family were found to be followed in multiple
centres: nevertheless, these families were considered
only once.
Overall, 40 different germline RET mutations were
identified. However, six families (6/250, 2.4%) were
negative for germline mutations, despite a more
accurate analysis covering the entire RET coding
sequence. The analysis of the prevalence of the different
RET mutations showed that the most frequent RET
amino acid substitution was Val804Met (49/250,
19.6%) followed by Cys634Arg (34/250, 13.6%;
Fig. 1). In addition, codon 634 at exon 11 was the
most frequently altered codon (nZ87, 34.8%; Fig. 2),
and consequently, exon 11 was the most frequently
altered exon.Phenotypes were defined in all centres following the
same criteria (26). According to this classification,
85/250 (34%) kindred were classified as MEN 2A,
17/250 (6.8%) as MEN 2B, and 144/250 (57.6%) as
FMTC. In 3/250 (1.2%) cases (Fig. 3), the presence of
a germline RET mutation was not correlated with a
clinically developed MTC, and the RET genetic screening
was performed for the evidence of hypercalcitoninemia
and C cell hyperplasia in two kindred (Fig. 3, families C
and D) and for Hirschsprung’s disease in one (Fig. 3,
family A). In 1/250 (0.4%) cases (Fig. 3, family B), the
mutation (Arg694Gln) was detected during a random
screening for RET polymorphisms in the general
population, and was not associated with MTC or
hypercalcitoninemia, in keeping with its lack of
in vitro-transforming activity, as previously reported
(40): these four kindred were classified as ‘Others’ and
the corresponding mutations as variants of unknown
significance (VUS). These four families and their
corresponding mutations were not considered in the
following statistical evaluation. As shown in Table 1,
the majority of MEN 2A cases were associated with
mutations at codon 634, while MEN 2B was exclusively
associated with the mutation at codon 918. Conversely,
the genotype–phenotype correlation in FMTCand others
was much more heterogeneous in terms of involved
codons. As previously observed (16, 18), the majority of
these two last groups of patients harboured a RET
germline mutation in a non-cysteine codon. Among
the six families without a RET germline mutation, we
distinguished five FMTC and one MEN 2A kindred.
As shown in Table 2, the comparison of the
prevalence of RET germline mutations in the present
study with those found in studies published by other
European Study Groups showed a statistically signi-
ficant difference (P!0.0001). In particular, there
was a significantly higher prevalence of Val804Met
(P!0.0001) and Ser891Ala (PZ0.0012) mutations in
the Italian study, which were relatively rare in both
EUROMEN and German groups. Conversely, a lowerwww.eje-online.org
Table 1 Prevalence of different RET mutations according to different phenotypes.
Phenotype
RET mutation
n (%)
MEN 2A
(nZ85)
MEN 2B
(nZ17)
FMTC
(nZ144)
Others
(nZ4)
Overall
(nZ250)a
Thr338Ile 1 (0.7) 1 (0.4)
Cys515Ser 1 (0.7) 1 (0.4)
Cys609Gly 1 (1.2) 1 (0.4)
Cys609Phe 1 (1.2) 1 (0.4)
Cys609Ser 1 (1.2) 1 (0.4)
Cys609Arg 1 (0.7) 1 (0.4)
Cys609Tyr 2 (1.4) 2 (0.8)
Cys611Gly 1 (0.7) 1 (0.4)
Cys618Arg 2 (2.4) 3 (2.1) 5 (2.0)
Cys618Gly 2 (1.4) 2 (0.8)
Cys618Ser 6 (4.1) 6 (2.4)
Cys618Tyr 1 (1.2) 1 (0.7) 2 (0.8)
Cys620Arg 1 (1.2) 3 (2.1) 4 (1.6)
Cys620Gly 1 (0.7) 1 (0.4)
Cys620Phe 1 (0.7) 1 (0.4)
Cys620Ser 2 (2.4) 1 (0.7) 3 (1.2)
Cys630Arg 1 (0.7) 1 (0.4)
Cys630Tyr 3 (2.1) 3 (1.2)
Cys634Arg 30 (35.3) 4 (2.8) 1 (0.7)
Cys634Gly 5 (5.9) 1 (0.7) 6 (2.4)
Cys634Phe 4 (4.7) 3 (2.1) 7 (2.8)
Cys634Trp 3 (3.5) 1 (0.7) 4 (1.6)
Cys634Tyr 21 (24.7) 7 (4.9) 28 (11.2)
Cys634Ser 6 (7.0) 6 (2.4)
Cys634Thr 1 (1.2) 1 (0.4)
Cys634Val 1 (1.2) 1 (0.4)
Val648Iso 2 (50) 2 (0.8)
Lys666Met 1 (0.7) 1 (0.4)
Arg694Gln 1 (25) 1 (0.4)
Glu768Asp 1 (1.2) 8 (5.6) 9 (3.6)
Leu790Phe 8 (5.6) 8 (3.2)
Tyr791Phe 1 (0.7) 1 (25) 2 (0.8)
Val804Leu 3 (2.1) 3 (1.2)
Val804Met 3 (3.5) 46 (31.9) 49 (19.6)
Met848Thr 1 (0.7) 1 (0.4)
Ala883Thr 1 (0.7) 1 (0.4)
Ser891Ala 23 (15.9) 23 (9.2)
Ser904Phe 1 (0.7) 1 (0.4)
Met918Val 2 (1.4) 2 (0.8)
Met918Thr 17 (100) 17 (6.8)
aSix families (five FMTC and one MEN 2A) did not harbour any RET mutation.
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Tyr791Phe (PZ0.0002) was observed in the present
study, especially when compared with the German
study. A statistically significant difference was also
observed in the prevalence of Met918, which was much
higher in the German study with respect to the others
(PZ0.0032) and of Cys634, which was much higher in
the EUROMEN study (P!0.0001).
We also observed a high prevalence of several
mutations affecting non-cysteine codons, some of
which were never reported before. As shown in
Table 3, when we compared the percentage of RET
mutations affecting cysteine and non-cysteine codons,
we found a statistically significant difference among the
three groups with a higher prevalence of mutations
affecting non-cysteine codons in our study (P!0.0001).www.eje-online.orgDiscussion
MEN 2 syndromes are rare, and affected patients are
usually referred to specialized centres. In the present
study, the majority of the Italian referral centres replied
to an invitation to share data on familial MTC and the
data collected, which correspond to the largest
European study available to date, clearly show a
widespread distribution of cases at a national level.
We are aware that this survey is not complete due to the
fact that a few centres did not reply to our invitation and
because a few MEN 2 families may be followed in
peripheral centres which could not be reached by our
first call for families. Nevertheless, the majority of the
Italian referral centres have been contacted and, with a
few exceptions, they replied to our invitation.
Table 2 Prevalence of RET germline mutations in hereditary
medullary thyroid carcinoma: a comparison among three different
European studies.
RET mutation
n (%)
Germany
(nZ141)
EUROMEN
(nZ145)
Italy
(nZ246)a
Met918 21 (15) 4 (2.8) 20 (8.1)
Cys634 57 (40) 98 (67.6) 86 (34.9)
Asp631 1 (0.7) 0 0
Cys630 1 (0.7) 1 (0.8) 4 (1.6)
Cys620 10 (7) 10 (6.9) 9 (3.6)
Cys618 7 (5) 10 (6.9) 15 (6.0)
Cys611 2 (1.4) 4 (2.8) 1 (0.4)
Cys609 1 (0.7) 1 (0.8) 6 (2.4)
Leu790 17 (12) 7 (4.8) 8 (3.2)
Tyr791 10 (7) 3 (2.1) 1 (0.4)
Val804 9 (6.4) 3 (2.1) 52 (21.1)
Ser891 3 (2.2) 3 (2.1) 23 (9.3)
Glu768 2 (1.4) 1 (0.8) 9 (3.6)
Ala883 0 0 1 (0.4)
Cys515 0 0 1 (0.4)
Lys666 0 0 1 (0.4)
Met848 0 0 1 (0.4)
Ser904 0 0 1 (0.4)
Thr338 0 0 1 (0.4)
No mutations 0 0 6 (2.4)
aVUS have been excluded.
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MEN 2 in Italy, which indeed was not the aim of this
study, the study was large enough to show the
prevalence and the distribution of both different RET
gene mutations and different MEN 2 phenotypes (i.e.
MEN 2A, 2B, and FMTC). We observed an overall
different distribution of several germline RET mutations,
and in particular, we found that Val804Met, which is
localized in exon 14, is the most frequent RET mutation
in Italy. A high prevalence of Val804Met mutation was
firstly reported in a Sardinian study, and this finding
was interpreted as a possible consequence of the
remarkable influence of genetic drift and of the founder
effect in the history of this population living isolated for
several centuries (21). As a matter of fact, several other
genetic diseases have shown a different (and often
higher) prevalence in Sardinia with respect to other
Italian regions (27–29). However, this hypothesis was
not confirmed by the present study, showing an overall
high prevalence of Val804Met mutation in Italy with
respect to other European countries (16, 23, 24, 30).
Moreover, in our study, the presence of a founder effect
was excluded, because the analysis of the pattern of the
RET gene single-nucleotide polymorphisms in indexTable 3 Comparison of prevalence of cysteine and non-cysteine RET
Study Cysteine Non-cysteine
German Austria (nZ141) 56 44
EuroMen (nZ145) 86 14
ItaMEN (nZ240)a 50.8 49.2
aThe six RET-negative families and the four ‘Others’ families have been excludcases harboring the Val804Met mutation was different
in different patients (data not shown).
With a few exceptions (31–34), RET Val804Met
mutation is usually correlated with the FMTC pheno-
type, and in the majority of cases, the aggressiveness
of the thyroid tumor is relatively low. However, it has
been demonstrated that this mutation is refractory
to many tyrosine kinase inhibitors (TKI) (35), which
nowadays are considered the best target therapy under
development (36). It is of concern that if Val804Met
mutation is so prevalent, some of these patients might
develop an aggressive form with no possibility of being
treated with TKI.
When comparing the RET mutations prevalence in
our study with those reported in other European
study (2, 16, 18, 23–25, 31), we also observed a higher
prevalence of Ser891Alamutation in exon 15.We found
that this mutation was mainly present, although not
exclusively, in a well-defined area of Northern Italy, and
the possibility of a founder effect is under investigation
(37). Conversely, a lower prevalence of both Leu790Phe
and Tyr791Phe was evident especially when the
comparison was performed between the German study
and ours. It is conceivable that different ethnic origins of
the patients included in the different series may explain
these statistically significant differences.
It is worth noting that a certain number of RET
mutations described in the present study have never
been reported before (http://arup.utah.edu/database/
MEN2/MEN2_welcome.php). Some of these mutations
have been found in patients affected with MTC, while
others were found in subjects screened for other reasons
(generally hypercalcitoninemia). While some of them
have been studied for their transforming ability (38–40)
others, such as Lys666Met, Met848Thr, Met918Val,
Ser904Phe, Thr338Ile, and Val648Iso, have not been
investigated. Since at least one of these mutations
(Arg694Gln) was proven to be devoid of transforming
activity (40), caution should be exercised in the
interpretation of the actual pathogenic role of these
rare mutations. Nevertheless, we previously reported a
germline RET mutation associated with MTC in two
homozygous brothers but not in four other hetero-
zygous relatives (38). Although the transforming
activity of this RET mutation was proven, we can
speculate that there are RET mutations with a very low
transforming activity, not necessarily observed in
‘in vitro studies’, which require a long period of time
or a second reinforcing mutation on the other allele to
trigger the tumoral transformation. As a matter of fact,mutations in the three different European studies.
P References
Frank-Raue et al. (1996) (25)
P!0.0001 Machens et al. (2003) (24)
Present study
ed.
www.eje-online.org
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rare RET mutations are usually very small or even
restricted to a single-index case found with a germline
RET mutation. It must be remembered that one of the
inclusion criteria in this study was that all MTC,
including those presenting as sporadic form from a
clinical and anamnestic point of view, should have been
screened for RET mutations in the six most commonly
altered exons. Furthermore, in our clinical practice, it is
common that when no mutations are found in the most
commonly altered codons, other exons are investigated
thus increasing the possibility of finding new mutations
outside the hot spots. This very intensive search for RET
mutations might surface rare mutations which are
mainly located in the non-cysteine RET coding codons.
To reveal the risk profile of these uncommon RET
mutations, a larger recruitment of family members is
desirable to better correlate genotype and phenotype.
In vitro studies of the tumoral transforming activity are
also necessary. At present, these mutations could be
considered as allelic variants (41, 42).
While the phenotype of MEN 2A and 2B is relatively
easy to be defined because based on the positive family
history and/or the association with other endocrine and
non-endocrine diseases (7, 15, 26), the definition of
FMTC is more challenging because it may be thought
that the other endocrine neoplasms are not yet
developed at the time of FMTC diagnosis. The problem
is negligible in large multigenerational families with
several members affected by only MTC, while in smaller
families with few affected members caution should be
posed as there is the risk of underestimating the
possibility of later developing PHEO. This problem is of
particular relevance because, at least in our study, the
prevalence of FMTC is much higher than that reported
before and the FMTC phenotype is largely prevalent
with respect to the others (16, 25, 33). To our
knowledge, this high prevalence of FMTC (56.6%) has
never been reported before and, in our opinion, this
finding is related to both the more recent introduction of
the RET screening in the work-up of apparently sporadic
MTC and the more extensive search for RET mutations
in non-hot spot regions of the gene (18, 32, 43).
In conclusion, this study allowed us to have a more
comprehensive vision of the RET mutations and MEN 2
phenotypes distribution and prevalence in Italy. To our
knowledge, this is the first and unique study collecting
data from the majority of Italian centres involved in the
diagnosis and treatment of thyroid cancer. We observed
several statistically significant and peculiar differences
in the prevalence of specific RET mutations with respect
to other European studies. These differences can be due
both to the different ethnical origins of the patients
belonging to the different studies and also to the
particular attention in looking for germline RET
mutations also in apparently sporadic MTC which, if
they turn out to be hereditary, are more frequently
associated with non-cysteine RET mutations. Thesewww.eje-online.orglatter hypotheses can also explain the other relevant
result of this study showing that FMTC is the most
prevalent MEN 2 phenotype, at least in Italy.Declaration of interest
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